From October 7-9, the Drug Information Association (DIA), FDA and Pharmaceutical Research and Manufacturers of America (PhRMA) will collaborate to host a "Progression-Free Survival Oncology Workshop" in Bethesda, MD.

Progression-Free Survival (PFS) refers to the length of time during and after treatment in which a patient living with a disease does not get worse. The endpoints for PFS are more and more frequently used in the evaluation and approval of oncology drugs.

Representatives from the FDA, National Cancer Institute and PhRMA will discuss how they view PFS clinically, in radiology, and for statistical evaluation. Richard Pazdur, MD, Director, Office of Oncology Drug Products, CDER, FDA, is keynote speaker.

A total of seven sessions and two tutorials are scheduled including:
- Radiological Evaluation of PFS
- Regulatory Considerations
- Time to Event Analysis for Non-Statisticians and
- Statistical Methods for Interval Censored Data Analyses

For more information or to register, visit diahome.org or call (215) 442-6100.